Effect of Cimetidine 800 mg h.s. and 300 mg q.i.d. on the Pharmaceutics of Warfarin in Patients Receiving Maintenance Warfarin Therapy, M. J. Sax, W. Randolph, Karl E. Peace, S. Chretian, William O. Frank, D. R. Gray, L. McCree, Alan Braveman, F. Wyle, B. J. Jackson, M. Beg
Karl E. Peace

Determining the Optimal Dosage Regimen for H2-receptor Antagonist Therapy – a dose validation approach, M. D. Young, William O. Frank, Brian Dickson, Karl E. Peace, Alan Braveman, W. Mounce
Karl E. Peace